Holen Sie sich die Stockscreener-App
2.85
0.35%
0.01
Perspective Therapeutics Inc Aktie (CATX) Neueste Nachrichten
Minerva Surgical (NASDAQ:UTRS) versus Perspective Therapeutics (NYSE:CATX) Financial Contrast - Defense World
Perspective Therapeutics: Definitely Not Looking Overvalued Now - Seeking Alpha
Pliant Therapeutics Inc (PLRX): A New Perspective - Stocks Register
Neuroendocrine Tumor Market to Reach New Heights in Growth by 2034, DelveInsight Predicts - News Channel Nebraska
Targeted Alpha Therapy Market, Drugs Approval, Proprietary Technologies & Clinical Trials: 20+ Drugs of Targeted Alpha Therapy In Clinical Trials - GlobeNewswire Inc.
Perspective Therapeutics' SWOT analysis: radiopharmaceutical stock faces pivotal moment - Investing.com
BNP Paribas Financial Markets Buys 44,174 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Charles Schwab Investment Management Inc. Acquires 298,778 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
Walleye Capital LLC Sells 494,706 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - MarketBeat
Perspective Therapeutics, Inc. (NYSE:CATX) Director Acquires $100,003.75 in Stock - MarketBeat
Janus Henderson Group PLC Has $64.01 Million Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - MarketBeat
Fmr LLC Purchases 5,370,392 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - MarketBeat
Perspective Therapeutics CEO Johan Spoor buys $30,132 in stock By Investing.com - Investing.com Canada
Perspective Therapeutics CEO Johan Spoor buys $30,132 in stock - Investing.com India
Perspective Therapeutics, Inc. (NYSE:CATX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Perspective Therapeutics CFO Jonathan Hunt acquires $48,974 in stock - Investing.com India
Perspective Therapeutics CFO Jonathan Hunt acquires $48,974 in stock By Investing.com - Investing.com Nigeria
Perspective Therapeutics selloff a buying opportunity, says JonesResearch - MSN
Insider Buying: Jonathan Hunt Acquires Shares of Perspective The - GuruFocus.com
Perspective Therapeutics director Robert Williamson acquires shares worth $22,813 - Investing.com
Jonathan Robert Hunt Acquires 12,829 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) Stock - MarketBeat
Perspective Therapeutics to Participate in Upcoming Investor Conferences in December - The Manila Times
Perspective Therapeutics to Present at Piper and Evercore Healthcare Conferences in December | CATX Stock News - StockTitan
Perspective Therapeutics (NYSE:CATX) Rating Lowered to “Neutral” at Bank of America - Defense World
Perspective Therapeutics price target lowered to $9 from $17 at B. Riley - TipRanks
Perspective Therapeutics, Inc. (NYSE:CATX) CEO Johan M. Spoor Acquires 14,500 Shares - MarketBeat
Perspective Therapeutics CEO Johan Spoor buys $100,468 in stock - Investing.com
Perspective Therapeutics price target lowered to $16 from $25 at RBC Capital - Yahoo Finance
Perspective Therapeutics downgraded to Neutral from Buy at BofA - Yahoo Finance
Perspective Therapeutics (NYSE:CATX) Price Target Cut to $16.00 by Analysts at Oppenheimer - Defense World
Perspective Therapeutics' SWOT analysis: radiopharmaceutical stock faces challenges, opportunities - Investing.com
Perspective Therapeutics shares hold Outperform as RBC adjusts expectations for progress - Investing.com Nigeria
Perspective Therapeutics (NYSE:CATX) Rating Lowered to Neutral at Bank of America - MarketBeat
Autonomix Medical (NASDAQ:AMIX) vs. Perspective Therapeutics (NYSE:CATX) Critical Review - Defense World
Perspective Therapeutics stock downgraded to Neutral By Investing.com - Investing.com Nigeria
Perspective Therapeutics stock downgraded to Neutral - Investing.com India
Perspective Therapeutics price target lowered to $16 from $22 at Oppenheimer - TipRanks
Stock market news: Perspective Therapeutics -44.33%, Pyxis Oncology -42.93% among top losers during mid day trading - Business Upturn
Stock market news: SKK Holdings Limited declined by 51.53% while SCWorx Corp. surged by 101.02% during mid day trading - Business Upturn
Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings - Benzinga
Stock market today: Pyxis Oncology plunges by 47.25% while Perspective Therapeutics declines by 46.68% in early trading - Business Upturn
Stock market today: SCWorx Corp. gains 141.81% while Pyxis Oncology down by 46.41% in early trading - Business Upturn
Perspective stock slips after radio pharma data (CATX:NYSE) - Seeking Alpha
Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium - The Manila Times
Cantor Fitzgerald Has Positive View of CATX FY2024 Earnings - MarketBeat
1.54%
Kapitalisierung:
|
Volumen (24h):